- Home
- TVRD vs ANNX Comparison
TVRD vs ANNX Comparison
Compare TVRD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- ANNX
- Stock Information
- Founded
- TVRD 2017
- ANNX 2011
- Country
- TVRD United States
- ANNX United States
- Employees
- TVRD N/A
- ANNX N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- ANNX Health Care
- Exchange
- TVRD Nasdaq
- ANNX Nasdaq
- Market Cap
- TVRD 246.5M
- ANNX 263.3M
- IPO Year
- TVRD N/A
- ANNX 2020
- Fundamental
- Price
- TVRD $24.14
- ANNX $2.35
- Analyst Decision
- TVRD Strong Buy
- ANNX Strong Buy
- Analyst Count
- TVRD 5
- ANNX 4
- Target Price
- TVRD $59.20
- ANNX $12.50
- AVG Volume (30 Days)
- TVRD 38.6K
- ANNX 1.6M
- Earning Date
- TVRD 08-21-2025
- ANNX 08-11-2025
- Dividend Yield
- TVRD N/A
- ANNX N/A
- EPS Growth
- TVRD N/A
- ANNX N/A
- EPS
- TVRD N/A
- ANNX N/A
- Revenue
- TVRD N/A
- ANNX N/A
- Revenue This Year
- TVRD N/A
- ANNX N/A
- Revenue Next Year
- TVRD N/A
- ANNX N/A
- P/E Ratio
- TVRD N/A
- ANNX N/A
- Revenue Growth
- TVRD N/A
- ANNX N/A
- 52 Week Low
- TVRD $8.13
- ANNX $1.29
- 52 Week High
- TVRD $34.31
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- TVRD N/A
- ANNX 45.17
- Support Level
- TVRD N/A
- ANNX $2.29
- Resistance Level
- TVRD N/A
- ANNX $2.62
- Average True Range (ATR)
- TVRD 0.00
- ANNX 0.18
- MACD
- TVRD 0.00
- ANNX -0.01
- Stochastic Oscillator
- TVRD 0.00
- ANNX 26.42
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.